



Supplement Figure 1



Supplement Figure 2



Supplement Table 1

PSMA compared with Choline PET Scan for Recurrent Prostate cancer						
Outcomes	No of participants (studies) Follow-up	Certainty of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects		
				Risk with placebo	Risk difference with PSMA PET Scans	
Overall Detection Rates	356 (3 observational studies)	⊕⊕○○ LOW	OR 2.27 (1.06 to 4.85)	669 per 1,000	152 more per 1,000 (13 more to 239 more)	
Detection Rates after BCR at PSA thresholds less than 2ng/ml	148 (2 observational studies)	⊕○○○ VERY LOW	OR 2.37 (0.61 to 9.17)	486 per 1,000	205 more per 1,000 (120 fewer to 410 more)	

PSMA compared with Choline PET Scan for Recurrent Prostate cancer

Outcomes	No of participants (studies) Follow-up	Certainty of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with placebo	Risk difference with PSMA PET Scans

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; OR: Odds ratio

GRADE Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
